Browse by author
Lookup NU author(s): Professor Catharien Hilkens
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Clinical studies with cellular therapies using tolerance-inducing cells, such as tolerogenic antigen-presenting cells (tolAPC) and regulatory T cells (Treg) for the prevention of transplant rejection and the treatment of autoimmune diseases have been expanding the last decade. In this perspective, we will summarize the current perspectives of the clinical application of both tolAPC and Treg, and will address future directions and the importance of immunomonitoring in clinical studies that will result in progress in the field.
Author(s): Ten Brinke A, Martinez-Llordella M, Cools N, Hilkens CMU, van Ham SM, Sawitzki B, Geissler EK, Lombardi G, Trzonkowski P, Martinez-Caceres E
Publication type: Review
Publication status: Published
Journal: Frontiers in immunology
Online publication date: 22/02/2019
Acceptance date: 21/01/2019
ISSN (electronic): 1664-3224
Publisher: NLM (Medline)
PubMed id: 30853957